AMENDMENT TO THE SPECIFICATION:

Please replace the paragraph beginning on page 3, line 12 with the following amended paragraph:

Suitable CXCR2 inhibitors which are useful in the present invention include, but are not limited to those compounds disclosed in US Patent No. 5,684,032 ; ~~WO 96/25157~~ US Patent No. 6,005,008; US Patent No. 5,780,483 ; ~~WO 97/35572~~ US Patent No. 5,955,492; ~~WO 97/49286~~ US Patent No. 6,271,261; WO 97/49399; ~~WO 97/49680~~ US Patent No. 6,133,319; WO 97/49287; ~~WO 98/07418~~ US Patent No. 6,214,881; ~~WO 97/49400~~ US Patent No. 6,218,539; ~~WO 98/05329~~ US Patent No. 6,177,448; ~~WO 98/05317~~ US Patent No. 6,248,785; WO 98/05328 ; WO 98/06398 ; ~~WO 98/06397~~ US Patent No. 6,204,294; ~~WO 98/06399~~ US Patent No. 6,335,352; WO 98/06262 ; WO 98/06701 ; ~~WO 98/32439~~ US Patent No. 6,300,325; ~~and~~ WO 98/32438; ~~Attorney Docket No.: P50708, PCT US98/18569, filed September 4, 1998~~ US Patent No.6,297,265; and ~~Attorney Docket No.: P50709, PCT US98/18563, filed September 4, 1998~~ US Patent No.6,316,478.

AMENDMENTS TO THE CLAIMS

1. (original) A method of inhibiting or blocking the binding of human neutrophils to activated endothelial cells in a patient in need thereof, which method comprises administering to said patient an effective amount of a compound which binds the CXCR2 receptor.

2. (currently amended) The method according to claim 1 wherein the compound is N-[2-Hydroxy-4-cyanophenyl]-N'-[2-bromophenyl] urea, or N-[2-Hydroxy-4-~~nitophenyl~~ nitrophenyl]-N'-(2-bromophenyl)urea or a pharmaceutically acceptable salt thereof.

3. (original) The method according to claim 1 which further comprises a compound which also binds to the CXCR1 receptor.

4. (previously presented) A method of inhibiting or blocking T-cell mediated chemotaxis in a patient in need thereof, which method comprises administering to said patient an effective amount of a compound which binds the CXCR2 receptor.

5. (previously presented) The method of according to claim 4 wherein the compound is N-[-Hydroxy-4-cyanophenyl]-N"-[2-bromophenyl] urea, or N-2[-Hydroxy-4-nitrophenyl]-N'-(2-bromophenyl) urea or a pharmaceutically acceptable salt thereof.

6. (original) The method according to claim 4 which further comprises a compound which also binds to the CXCR1 receptor.